Toyin Adewole, MD, MPH

Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric atten...

Stefan Schwabe , MD, PhD;

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

11/22/2019

Extended-Release Viloxazine (SPN-812) 200 mg or 400 mg for the Treatment of ADHD in Adolescents: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric atten...

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Stefan Schwabe , MD, PhD;

11/22/2019

Extended-Release Viloxazine (SPN-812) 100 mg or 200 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-defic...

Azmi Nasser , PhD;

Joseph Hull , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Stefan Schwabe , MD, PhD;

11/22/2019

Update on a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating SPN-810 for the Treatment of Impulsive Aggression (IA) in Pediatric Patients with ADHD

Background: Aggression is one of the most common reasons for psychiatric referral in children. The most prevalent subtype of maladaptive aggression is IA – which is reactive, overt, and o...

Azmi Nasser , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Jiahong Xu , MS, MPH;

Ronald Marcus , MD;

03/01/2019